EvenseJohnson syndrome-induced mortality cases from 1999 to 2008 in the National Health Insurance coverage databank. Yr1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 TotalCases8 6 8 eight six 12 12 5 20 26Age D of acute admission D of chronic admission Total annual price Total annual drug expense (yr; mean SD) (imply SD) (mean SD) (N.T. dollars/per particular person) (N.T. dollars/per individual)67.0 57.two 62.5 56.three 66.two 65.four 68.7 75.four 70.3 75.0 68.2 28.eight 27.9 24.six 28.5 24.1 21.7 14.3 eight.8 13.5 14.six 19.7 14.4 23.1 8.4 13.7 19.0 14.3 15.two 15.eight 15.5 14.four 14.8 7.5 26.1 9.4 12.0 6.three 11.five 16.2 13.1 14.0 12.8 13.8 0000000.4 0100.2 0 0 0 0 0 0 1.1 0 4.4 0 2.0 164,901,0000 522,811,6667 111,582,2500 209,861,6154 351,826,1667 264,409,0769 194,497,5714 214,781,7778 156,656,0714 167,165,0294 205,599,1342 35,645,2500 155,461,5556 24,568,8750 65,318,2308 97,085,6667 78,058,1538 47,730,3571 51,899,2222 39,664,5714 33,776,9706 52,932,SD common deviation.j o u r n a l o f f o o d a n d d r u g a n a l y s i s 2 4 ( two 0 1 six ) 4 two 7 e4 3Phenobarbitala Phenytoina Tenoxicama Piroxicama Sulfadoxinea Sulfamethoxazole/TMPa CarbamazepineaTable 2 e Clinical features of 111 patient death circumstances.IGF-I/IGF-1, Human (70a.a) Qualities Total situations N ( )a Drugedrug interaction N ( )a Nondrug edrug interaction N ( )a8 (50.0) 8 (50.0) 4 (25.0) 12 (75.0) 8 (50.0) 8 (50.0) 11 (68.eight) five (31.2) 9 (56.3) 7 (43.7) 13 (81.3) 3 (18.7) 16 (one hundred.0) 0 (0) 16 (100.0) 0 (0) 13 (81.three) 3 (18.7) 15 (93.eight) 1 (6.two) 13 (81.three) three (18.7) 14 (87.five) 2 (12.five) 15 (93.eight) 1 (six.two) 14 (87.five) 2 (12.five) 15 (93.eight) 1 (six.2) 14 (87.5) 2 (12.5) 15 (93.eight) 1 (6.two)pAllopurinola110 (99.1) 1 (0.9)95 (100.0) 0 (0)0.0144.DiscussionOur study could be the very first population-based, nested case-control study applying a information set of 111 SJS-induced fatality patientsAllopurinol Carbamazepine Sulfamethoxazole/TMP Sulfadoxine Piroxicam Tenoxicam Phenytoin Phenobarbital Ampicillin Cephalexin Erythromycin Vancomycin Doxycycline Minocycline Ethambutolp 0.05. p 0.0001. a All data have been statistical analyzed working with Chi-square tests.Table 3 e Drugedrug interactions.d p 0.695 p 0.782 p 0.783 p 0.695 p 0.167 p 0.695 p 0.308 p 0.Serpin A3 Protein Source 049 p 0.695 p 0.473 p 0.962 p 0.308 p 0.695 p 0.108 (97.three) 3 (2.7)94 (98.9) 1 (1.1)0.009p 0.05. TMP trimethoprim. a All data were tested applying analysis of variance.Sex Male Female Age (yr) 65 65 Allopurinol No Yes Carbamazepine No Yes Baktar No Yes Sulfadoxine No Yes Piroxicam No Yes Tenoxicam No Yes Phenytoin No Yes Phenobarbital No Yes Ampicillin No Yes Cephalexin No Yes Erythromycin No Yes Vancomycin No Yes Doxycycline No Yes Minocycline No Yes Ethambutol No Yes30 (27.0) 81 (73.0) 81 (73.0) 30 (27.0) 106 (95.PMID:36717102 5) five (four.5) 98 (88.3) 13 (11.7) 108 (97.3) three (two.7) 110 (99.1) 1 (0.9) 110 (99.1) 1 (0.9) 108 (97.three) three (two.7) 109 (98.2) 2 (1.eight) 108 (97.three) three (two.7) 108 (97.three) three (2.7) 110 (99.1) 1 (0.9) 106 (95.5) 5 (four.5) 109 (98.two) two (1.8)26 (27.4) 69 (72.6) 73 (76.eight) 22 (23.2) 95 (one hundred.0) 0 (0) 89 (93.7) 6 (six.three) 95 (one hundred.0) 0 (0) 94 (98.9) 1 (1.1) 94 (98.9) 1 (1.1) 95 (one hundred.0) 0 (0) 94 (98.9) 1 (1.1) 95 (100.0) 0 (0) 94 (98.9) 1 (1.1) 95 (one hundred.0) 0 (0) 92 (96.eight) 3 (3.2) 94 (98.9) 1 (1.1)0.0.025 p 0.167 p 0.848 p 0.717 p 0.829 p 0.848 d p 0.848 p 0.893 p 0.797 p 0.848 p 0.925 p 0.812 p 0.893 p 0.848 p 0.925 p 0.695 d p 0.0001 p 0.662 p 0.697 p 0.848 p 0.0001 p 0.785 p 0.601 p 0.697 p 0.848 p 0.630 p 0.785 p 0.697 p 0.848 p 0.782 p .0001 d p 0.409 p 0.463 p 0.717 p 0.015 p 0.607 p 0.324 p 0.463 p 0.717 p 0.364 p 0.091 p 0.463 p 0.717 p 0.783 p 0.662 p 0.409 d p 0.045 p 0.829 p 0.662 p 0.75.